Health

Vertex Drug Scrutiny

Updated 2026-10-29 13:35 UTC 1 source Negative

Ahead of its FDA approval, Vertex's kidney disease drug is under intense scrutiny for potential infection risks. The company faces significant regulatory and market challenges.

Coverage timeline — 1 article

STAT News

STAT+: Vertex kidney disease drug scrutinized for infection risk

Ahead of its FDA approval decision on Nov 30, Vertex's kidney disease drug is being heavily scrutinized for infection risk.

2026-10-29 13:25 UTC